Biobetter on Investor Village has what I think is an interesting post on upcoming events.
Abstract #314 sticks out to me as I'm guessing we will see some patient data for Cabo treated bladder cancer
Here are the abstract titles for ASCO GU
Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib.
Paul G. Corn, MD, PhD
Poster Board: #D13
Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).
Andrea B. Apolo, MD
Poster Board: #J7
I don't know if the February 15 think tank is part of ASCO GU, but the title leaves me interested in what KOL's current thoughts may be in advanced prostate cancer.
Friday, February 15, 2013, Orlando, FL, 7:00 PM – 9:00 PM (Eastern Time)
Current Clinical Controversies and Promising Therapeutic Strategies in Advanced Prostate Cancer: A Live Clinical Investigator Think Tank
"I don't know if the February 15 think tank is part of ASCO GU, but the title leaves me interested in what KOL's current thoughts may be in advanced prostate cancer."
With the ongoing industry-wide overtures wrt bone mets management - and all recent press coverage of integral bone-health clinics cropping up within the urology community, I have the highest expectations that Cabo will play quite well into any prudent discussion on advanced PC.
Thanks for the update, Hbomb.
Andrea Apolo is the lead investigator for the phase 2 human trial for Cabo in bladder cancer, and the wording in abstract title #314 leads me to believe the correlative studies may involve preclinical followup that includes patients in that phase 2 trial.
Bump. We need to maintain focus.
The short MB traffic is getting in the way.
Someone was asking about catalysts.
These are the potential short term drivers. Hopefully later this year we get some OS data from the ongoing EXAM trial. It'd be nice to hear some OS data from the P2 mCRPC RDT as well. I'm convinced it's the reason Dr Schwab placed her most recent bet.